The Multiple Myeloma Research Foundation Inc

MMRF accomplishments for 2024 the Multiple Myeloma Research foundation, inc. and its wholly owned subsidiaries, the Multiple Myeloma Research consortium, llc ("mmrc") and Myeloma investment fund, llc ("mif"), collectively referred to as "the MMRF," is the largest nonprofit in the world solely focused on accelerating a cure for each and every Multiple Myeloma patient. The MMRF drives the development and delivery of next-generation therapies, leverages data to identify optimal and more personalized treatment approaches and empowers Myeloma patients and the broader community with information and resources to extend their lives. Central to the MMRF's mission is its commitment to advancing health equity so that all Myeloma patients can benefit from the scientific and clinical advances they pursue. Since its incorporation on january 13, 1998, the MMRF has committed over $600 Million for Research, opened nearly 100 clinical trials, and helped bring 15+ fda approved therapies to market, which have tripled the life expectancy of Myeloma patients. In 2024 the MMRF invested $30m in urgent Research programs and support services for Myeloma patients. Through the Myeloma investment fund (mif), we invested in five early-stage biotech companies pursuing innovative, potentially game-changing treatments for Myeloma. We launched the groundbreaking horizon clinical trials program, enrolling the first patient back in november. As part of our commitment to health equity, we appointed a chief diversity officer and introduced several initiatives aimed at ensuring our clinical studies reflect the real-world u.s. Myeloma populationwith a goal of enrolling at least 20% black and 15% hispanic participants.